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Abstract
AIM
To investigate protective effects and molecular 
mechanisms of green tea polyphenols (GTP) on non-
alcoholic fatty liver disease (NAFLD) in Zucker fatty (ZF) 
rats.
METHODS
Male ZF rats were fed a high-fat diet (HFD) for 2 wk 
then treated with GTP (200 mg/kg) or saline (5 mL/kg) 
for 8 wk, with Zucker lean rat as their control. At the end 
of experiment, serum and liver tissue were collected 
for measurement of metabolic parameters, alanine 
aminotransferase (ALT) and aspartate aminotransferase 
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(AST), inflammatory cytokines and hepatic triglyceride 
and liver histology. Immunoblotting was used to detect 
phosphorylation of AMP-activated protein kinase (AMPK) 
acetyl-CoA carboxylase (ACC), and sterol regulatory 
element-binding protein 1c (SREBP1c). 
RESULTS
Genetically obese ZF rats on a HFD presented with 
metabolic features of hepatic pathological changes 
comparable to human with NAFLD. GTP intervention 
decreased weight gain (10.1%, P  = 0.052) and 
significantly lowered visceral fat (31.0%, P  < 0.01). 
Compared with ZF-controls, GTP treatment significantly 
reduced fasting serum insulin, glucose and lipids 
levels. Reduction in serum ALT and AST levels (both 
P  < 0.01) were observed in GTP-treated ZF rats. 
GTP treatment also attenuated the elevated TNFα 
and IL-6 in the circulation. The increased hepatic 
TG accumulation and cytoplasmic lipid droplet were 
attenuated by GTP treatment, associated with signifi-
cantly increased expression of AMPK-Thr172 (P  < 
0.05) and phosphorylated ACC and SREBP1c (both P  
< 0.05), indicating diminished hepatic lipogenesis and 
triglycerides out flux from liver in GTP treated rats. 
CONCLUSION
The protective effects of GTP against HFD-induced 
NAFLD in genetically obese ZF rats are positively 
correlated to reduction in hepatic lipogenesis through 
upregulating the AMPK pathway.  
Key words: Non-alcoholic fatty liver disease; Green 
tea polyphenols; Hepatic lipogenesis; Inflammatory 
cytokines; AMP-activated protein kinase 
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Core tip: The aim of this study was to examine 
the protective effects and molecular mechanism 
of green tea polyphenols (GTP) on non-alcoholic 
fatty liver disease (NAFLD)-induced by high fat diet 
(HFD) in genetically obese Zucker fatty (ZF) rats. 
The data of the study has demonstrated: (1) HFD-
ZF rats is an optimal rodent model of NAFLD for 
testing novel/natural agents for this disease; (2) GTP 
treatment ameliorated metabolic and histopathological 
abnormalities in HFD-ZF rats with NAFLD; and (3) GTP 
exerted a protective effect against hepatic steatosis 
and liver injury by attenuating inflammatory cytokines 
and inhibiting lipogenesis through upregulating AMPK 
activation. Therefore, GTP proves to be an effective 
natural agent for preventing NAFLD and reducing the 
risk of its severe complications such as nonalcoholic 
steatohepatitis, cirrhosis and hepatic cellular carcinoma. 
Tan Y, Kim J, Cheng J, Ong M, Lao WG, Jin XL, Lin YG, 
Xiao L, Zhu XQ, Qu XQ. Green tea polyphenols ameliorate 
non-alcoholic fatty liver disease through upregulating AMPK 
activation in high fat fed Zucker fatty rats. World J Gastroenterol 
2017; 23(21): 3805-3814  Available from: URL: http://www.
wjgnet.com/1007-9327/full/v23/i21/3805.htm  DOI: http://dx.doi.
org/10.3748/wjg.v23.i21.3805
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD), charac-
terised by excess accumulation of fat in the liver, 
has a dramatically rising incidence parallel with 
the increasing population of metabolic syndrome 
worldwide[1,2]. NAFLD is emerging as a potential health 
burden in society because hepatic lipid accumulation 
can trigger hepatocyte damage, inflammation and 
fibrogenesis leading to more serious liver disorders 
such as nonalcoholic steatohepatitis (NASH), cirrhosis 
and hepatic cellular carcinoma (HCC)[3]. In addition, 
increased liver lipids [triglyceride (TG), diglyceride, 
and ceramides] exacerbate hepatic insulin resistance 
subsequently leading to type 2 diabetes and 
cardiovascular complications[4,5]. Therefore, identifying 
strategies to reduce excessive fat accumulation in the 
liver, especially to decrease hepatic TG, is critical for 
treatment of NAFLD and prevention of its potential 
consequences such as cardiometabolic disease. 
Currently, no pharmacological therapy is approved 
for NAFLD. Several drug treatments for the manage-
ment of NAFLD have been proposed, but none have 
shown considerable efficacy on the whole spectrum 
of liver damage[6]. Lifestyle interventions involving 
exercise and weight loss are the only accepted 
treatments for this disease but are often difficult to 
maintain for NAFLD sufferers. Thus, there is an urgent 
need to discover agents targeted at elevated hepatic 
lipids and safe for long-term administration. 
Green tea (Camellia sinensis) contains natural 
catechins that is a heterogeneous class of polyphenolic 
compounds, mainly (-)-epigallocatechin-3-gallate 
(EGCG), with beneficial effects related to their 
antioxidant and anti-inflammatory properties[7]. 
Recently, green tea polyphenols (GTP) has received 
considerable attention for its metabolic effects against 
metabolic syndrome and type 2 diabetes[8]. Several lines 
of studies suggest that the anti-diabetic effects of GTP 
are probably due to suppressing appetite, modifying 
dietary fat emulsification in the gastrointestinal tract, 
inhibiting gastrointestinal lipolysis and reducing nutrient 
absorption[9-11]. Our previous studies have demonstrated 
that GTP has direct effects on glucose and lipid 
metabolism through enhancing glycogen synthesis and 
inhibiting lipogenesis in hepatocytes[12]. Based on the 
results of this in vitro study, we hypothesis that GTP can 
reduce hepatic lipid accumulation against fatty liver in 
vivo. 
NAFLD is a complex metabolic disease. Many 
epidemiological studies have demonstrated that 
overnutrition or inappropriate diet leads to insulin 
resistance, dyslipidaemia and chronic inflammation, 
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which significantly contribute to the development of 
NAFLD[13,14], in particular for those who have tendency 
for obesity genetically[15]. To evaluate effects of GTP on 
a rodent model that mimics most pathophysiological 
features of NAFLD in humans, Zucker fatty (ZF) rat, a 
genetic model of metabolic syndrome with obesity[16] 
was used in the study and fed with a high fat diet 
(HFD). There is increasing evidence that increased 
liver TG content is highly correlated to increased de 
novo lipogenesis[17]. AMP-activated protein kinase 
(AMPK) activity plays a vital role in mediating hepatic 
lipogenesis[18]. Recent studies have shown that AMPK 
activity is reduced by the factors implicated in the 
development of NAFLD, such as inflammation and 
obesity[19,20]. Therefore, inhibition of hepatic lipogenesis 
by AMPK activation is envisaged as a viable therapeutic 
strategy to prevent the initiation and progression of 
NAFLD[21]. Whether GTP improves both genetic and 
dietary factors implicated in NAFLD through activation 
of AMPK pathway, however, has not previously 
been addressed. In the current study, we tested 
the hypothesis that GTP would confer an effective 
therapy against obese- and HFD-induced NAFLD in 
rats through upregulating the AMPK pathway. Thus, 
protein molecules involved in AMPK-mediated hepatic 
lipogenesis were detected followed by a metabolic 
study in HFD-ZF rats with or without GTP treatment. 
MATERIALS AND METHODS
LC-MS analysis of polyphenols in green tea
The polyphenols extracted from green tea (98% purity) 
were analyzed using an Agilent 1200 series liquid 
chromatograph/mass selective detector equipped with 
QTOF 6510 mass spectrometer (Agilent Technologies). 
Mass spectrometry data were acquired and quantified 
with an EGCG standard. The concentration of other 
polyphenols were calculated using the EGCG standard 
(CAS No: 989-51-5, MF: C22H18O11, MW: 458.378 
and Purity: ≥ 99% (HPLC).
Animal and treatment
Male Zucker fatty (fa/fa) rats (ZF) and their lean 
littermates, aged 5-7 wk and approximately 160 g 
body weight, were supplied by the Monash Animal 
Research Platform (Monash University, Vic, Australia). 
The animal protocol designed to minimize pain or 
discomfort to the animals was approved by the Animal 
Care and Ethics Committee (ACEC # 2009-325A) 
of the University of Technology Sydney and was in 
accordance with the National Health and Medical 
Research Council of Australia Guidelines on Animal 
Experimentation. Rats were acclimatised in communal 
cages at 22 ℃, with a 12 h light-dark cycle (lights 
on 0700 h) for 1 wk and had ad libitum access to 
a standard chow diet (Gordon’s Specialty Stock 
Feed, Sydney, Australia) and water. ZF rats (n = 24) 
were fed a high-fat diet (HFD) for 2 wk. The energy 
percentage composition of the HFD was 59% fat, 20% 
carbohydrate, and 21% protein, with equal quantities 
of fibre, vitamins, and minerals to the standard chow 
diet. The HFD was replenished daily. After two weeks 
of HFD feeding, ZF rats were divided into two groups. 
The control group (ZF-Con; n = 12) was administered 
saline (5 mL/kg of body weight) and ZF rats in the 
GTP group (ZF-GTP; n = 12) was administered GTP 
at 200 mg/kg of body weight daily for 8 wk via oral 
gavage. HFD feeding was continued throughout the 8 
wk treatment period. Lean Zucker rats (Lean, n = 12) 
were fed a standard laboratory chow diet throughout 
the treatment period.
Determination of metabolic parameters, liver enzymes 
and insulin sensitivity
At the end of treatment, blood samples were collected 
from the tail of rats after an overnight fast (12 h). 
Fasting serum total cholesterols (TC), high-density 
lipoprotein cholesterol (HDL-C), triglycerides (TG) 
and non-esterified fatty acids (NEFAs) were analysed 
using enzymatic colorimetric kits obtained from Roche 
Diagnostic (Mannheim, Germany) and Wako Pure 
Chemical Industries (Osaka, Japan) respectively. Low-
density lipoprotein cholesterol (LDL-C) concentrations 
were calculated by Friedewald's formula: LDL-C 
(mmol/L) = TC - HDL-C - TG/2.2. Fasting serum 
insulin concentration was measured using a RIA kit 
(Linco Diagnostic Services Inc, St. Charles). Fasting 
serum glucose, alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) were determined 
by spectrophotometric analysis using commercial kits 
(Dialab, Vienna, Austria). All experimental assays were 
carried out according to the manufacturer’s instruction. 
Tissue collection and measurement of liver triglycerides 
At the end of the experiment, animals were anes-
thetized using inhalant aesthetic gas (isoflurane and 
nitrous oxide) after 12 h of fasting. Liver and visceral 
fat (epididymal and peri-rental adipose tissues) were 
quickly excised, washed by ice-cold PBS then stored 
at -80 ℃ for subsequent histological and molecular 
assays.
Approximately 50 mg of liver tissues was 
homogenized at 4 ℃ in RIPA lysis buffer (Sigma-
Aldrich, St. Luis, MO, United States). Lipids from the 
liver homogenate were extracted using chloroform/
methanol method (2:1), evaporated, and dissolved 
in 1 mL ethanol (Sigma-Aldrich, St. Luis, MO, United 
States). TG concentration was assayed using kits from 
Roche Diagnostic (Mannheim, Germany) following the 
manufacturers’ instructions.
Liver histological analysis
A small portion of frozen liver tissue was cut and 
embedded with pre-cooled optimal cutting compound 
(Torrance, CA, United States) for cryostat sectioning 
at 6 µm. The sections were mounted on microscope 
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pictogram per millilitre.
Western blotting
One hundred milligram of frozen liver samples 
was homogenized in 1 mL lysis buffer (Roche Diag-
nostics, Indianapolis, IN, United States). Then, the 
homogenates were centrifuged at 3000 g for 10 
min at 4 ℃. The supernatants were collected and 
the protein concentration of each supernatant was 
determined by the Bradford method. Total protein 
(20 µg) was separated to 7.5% SDS-polyacrylamide 
gel electrophoresis then transferred to 0.45 µmol/L 
polyvinyldenedifluoride (PVDF) membrane and 
immunoblotted with primary antibodies against 
phospho-AMPKα (Thr172), AMPKα, phospho-ACC 
(Ser79) and ACC (Cell Signaling Technology Inc, MA), 
SREBP-1c and β-actin (Santa Cruz, CA, United States) at 
1:1000 dilution and secondary antibodies (Santa Cruz, 
CA, United States) at 1:10000 dilution. Blots were then 
developed with enhanced chemiluminescence (ECL) 
(Pierce, IL, United States) according to manufacturer’
s instructions. The protein bands were visualized by 
ChemiDoc XRS systems (Bio-Rad Laboratories, CA, 
United States). The density of bands was quantified 
with Quality One 4.6.1 software (Bio-Rad, CA, United 
States) and the quantified results from 8 rats of each 
group were calculated as percentage of control lean 
rats for statistical analysis.
Statistical analysis
All values are expressed as mean ± SEM. Comparisons 
across the three groups were performed using one-
way ANOVA followed by post-hoc analysis of Tukey’s 
test to determine significant differences between the 
two groups using Prism version 6 (GraphPad Inc, San 
Diego, CA, United States). P value < 0.05 was con-
sidered statistically significant.
RESULTS
Effects of GTP on body weight and metabolic 
parameters 
Average food intake remained consistent and similar 
between ZF control rats and GTP treatment at 
approximately 17 g/rat per day for the duration of the 
study period. The body weight and visceral fat of ZF 
rat were significantly higher than their lean control, 
associated with hyperglycaemia and hyperlipidaemia 
(Table 1). No significant differences in liver weight 
were noted between ZF control and GTP-ZF rats. GTP 
treatment prevented HFD-induced weight gain by 
10.1% (P = 0.052) and significantly decreased visceral 
fat by 31.0% (P < 0.01) and lowered fasting serum 
glucose and insulin levels (Table 1, ZF-Con vs ZF-GTP 
group, both P < 0.05). GTP treatment also significantly 
reduced the elevated serum levels of cholesterol, TG 
and NEFAs by 25.4% (P < 0.05), 34.6% (P < 0.01), 
and 20.9% (P < 0.05), respectively, when compared 
slides then fixed with 10% formaldehyde solution 
for 48 h. The samples were then stained with 
Haematoxylin and Eosin (H&E) or Oil Red O (ORO, 
Sigma-Aldrich, St. Luis, MO, United States) to 
investigate architecture of the liver and hepatic lipid 
droplets. Stained ORO slides were visualized with the 
Olympus microscope and images were captured with 
an Olympus digital camera (DP70, Tokyo, Japan) using 
Image-Pro6.2 software (Media Cybernetics, Inc. MD, 
United States). Lipid droplets were quantified at least 
5 different high-power fields in a blinded way. For each 
group, liver samples from 6-8 rats were prepared and 
stained and six fragments from each liver were further 
analysed. All slides were scanned at an absolute 
magnification of 400X using Image-Pro6.2 software 
(Media Cybernetics, Inc. MD, United States) under a 
light microscopy (Olympus, BX51 microscope, Tokyo, 
Japan). Morphometric results are presented as area 
fractions-the percentage of specific counts in relation 
to total number of counted points.
Measurement of proinflammatory cytokines in 
circulation
Serum levels of TNF-α, interleukins (IL-6 and IL-10) 
and interferon gamma (IFNγ) were measured with 
a standard sandwich enzyme immunoassay method 
using the Bio-Plex Pro mouse cytokine assay kit (Bio-
rad Laboratories, Hercules, CA, United States) for the 
simultaneous quantification of TNF-α, ILs and IFNγ 
according to the manufacturer’s instructions. Resulting 
TNF-α, ILs and IFNγ levels were determined using a 
Bio-Plex MAGPIX array reader, which identified and 
quantified each specific reaction based on bead colour 
and fluorescent signal intensity and expressed as 
Table 1  Effects of green tea polyphenols on parameters 
associated with obesity and metabolism
Paradigm parameter Lean ZF-Con ZF-GTP
Initial body weight (g) 258.6 ± 9.5 369.8 ± 12.8b 370.4 ± 13.7
344.8 ± 8.4 449.6 ± 17.6b 404.1 ± 10.8
Body weight (g)
Food intake (g/d/rat)   23.13 ± 0.04 17.01 ± 0.33a 16.52 ± 0.51
Liver weight (g)   11.84 ± 0.41 13.51 ± 0.82a 12.73 ± 0.74
Visceral adipose (g)     1.96 ± 0.57   9.16 ± 0.17e    6.32 ± 0.21d
Glucose (mmol/L)     4.38 ± 0.54   7.54 ± 1.70a    6.60 ± 1.22c
Insulin (µU/L)     0.55 ± 0.04   77.7 ± 14.3e  38.64 ± 11.2c 
SHBG (nmol/L) 102.2 ± 6.9 82.6 ± 4.8a  91.2 ± 5.6c
Serum lipids levels
   Total cholesterol (mmol/L)     2.90 ± 0.07   5.42 ± 0.21b    4.04 ± 0.23c
   Triglyceride (mmol/L)     0.11 ± 0.01   0.75 ± 0.02e    0.49 ± 0.04d
   HDL (mmol/L)     2.64 ± 0.22   1.37 ± 0.21b    2.03 ± 0.07c
   LDL (mmol/L)   1.37 ± 0.2   4.28 ± 0.42e    2.46 ± 0.36c
   NEFAs (mmol/L)     0.76 ± 0.04   1.29 ± 0.03a    1.02 ± 0.07c
Zucker fatty (ZF) rat were fed high-fat diet for 2 wk then treated with 
saline (5 mL/kg of body weight), or green tea polyphenols (GTP, 200 
mg/kg of body weight) for 8 wk. Metabolic parameters are represented 
as mean ± SEM from 12 rats each group. aP < 0.05, bP < 0.01 and eP < 0.001 
vs lean rats; cP < 0.05 and dP < 0.01 vs ZF-Con rats. NEFA: Non-esterified 
fatty acids; SHBG: Sexual hormone binding globulin.
Tan Y et al . GTP for NAFLD
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with the ZF-Con rat. HFD feeding caused a 48.1% 
reduction of serum HDL level (ZF-Con vs Lean group, P 
< 0.01) while HDL level was significantly higher in GTP 
treated ZF rats than ZF-Con rats (Table 1, P < 0.05). 
Effects of GTP on hepatic ALT and AST levels in HFD fed 
ZF rats
When compared with the lean control, serum hepatic 
enzyme (ALT and AST) levels in HFD-fed ZF rats were 
increased by 6.2 fold (Figure 1A; 29.20 ± 4.01 U/L vs 
189.89 ± 20.69 U/L, P < 0.001) and 3 fold (Figure 1B; 
54.71 ± 17.88 U/L vs 183.14 ± 13.91 U/L, P < 0.001), 
respectively. GTP treatment significantly attenuated 
the elevated ALT and AST values (both P < 0.01) when 
compared with control ZF rats (Figure 1).
Effect of GTP on hepatic steatosis and TG content of 
HFD ZF rats
The macrovesicular steatosis and fat droplets were 
assessed in H&E and ORO-stained sections by light 
microscopy and digital image analysis (DAI). More 
microvesicular steatosis was observed on H&E stained 
sections of ZF control rats than ZF-GTP rats and no 
macrovesicular steatosis in the lean control (Figure 
2A). Fat filtration and hepatic steatosis were further 
confirmed with ORO-stained cryosections because 
ORO staining analysis is much higher sensitivity and 
specificity for hepatic steatosis. The elevated lipid 
accumulation was revealed by many lipid droplets in 
ORO-stained cryosections of ZF control rats compared 
to the lean control (Figure 2B). DIA results (Figure 2C) 
showed significant reduction in lipid droplets with GTP 
treated ZF rats, indicating that GTP greatly prevented 
lipid infiltrations and hepatic steatosis. 
Consistent with ORO-staining results, measurement 
of TG content in the liver showed that HFD ZF rats 
presented significantly higher hepatic TG by 4-fold 
compared to lean rats (13.65 ± 4.51 µmol/g vs 3.36 ± 
0.72 µmol/g; P < 0.01). Results in Figure 2D showed 
that GTP treatment significantly reduced hepatic TG 
content in HFD fed ZF rats (9.05 ± 2.87 µmol/g vs 
13.65 ± 4.51 µmol/g; P < 0.01).
Effects of GTP on inflammatory cytokines in circulation
Circulating inflammatory cytokines were assessed by 
enzyme immunoassay. Figure 3 shows significantly 
increased TNF-α and IL-6 in HFD-ZF control rats 
compared with the Lean control (P < 0.01 and P < 
0.05 respectively), whereas, GTP treatment markedly 
decreased the elevation of TNF-α and IL-6 (Figure 3A 
and B, both P < 0.05). IL-10 and IFNγ levels were no 
significant difference among three groups (Figure 3C 
and D). 
Effects of GTP on de novo lipogenesis pathway in the 
liver of ZF rats 
AMPK and ACC are key enzymes that regulate de novo 
lipogenesis in the liver and contribute considerably 
to overall metabolism of lipids[15-16]. Results in Figure 
4 show that expression of phospho-AMPKα (Thr172) 
was significantly lower in HFD fed ZF rats compared 
with the lean control rats (P < 0.05), and GTP ad-
ministration significantly enhanced expression of 
phospho-AMPKα (Thr172) (P < 0.05) in HFD ZF rats. 
A reduction of ACC (Ser79) phosphorylation was 
observed in the liver of HFD ZF rats, and this was 
reversed by GTP treatment in a similar manner to that 
phospho-AMPKα (Thr172) expression.
SREBP-1c, a key transcription factor regulating 
the gene expression of key enzymes implicated 
in upregulating de novo lipogenesis in the liver[22] 
was also detected by immunoblotting. HFD-fed ZF 
rats presented an approximate 1.75 fold increase in 
SREBP-1c expression in the liver compared to the lean 
control (Figure 5B; P < 0.01). GTP treatment abolished 
overexpression of SREBP-1c protein compared to ZF 
control rats (Figure 5B; P < 0.01).  
DISCUSSION
Hepatic steatosis is the first stage of NAFLD, which is 
mostly associated with increased de novo lipogenesis 
and obesity, however, it can progress to a more 
advanced form of the disease, NASH, hepatic necrosis, 




































Figure 1  Effect of green tea polyphenols on alanine transaminase (A) and aspartate transaminase (B) in high-fat diet Zucker fatty rats. Serum alanine 
transaminase (ALT) and aspartate transaminase (AST) concentrations were measured after 8 wk of daily treatment with saline (5 mL/kg; Lean, ZF-Con) or GTP (200 
mg/kg; ZF-GTP). Data are means ± SEM, n = 12 rats/group. bP < 0.01 vs Lean rats and dP < 0.01 vs ZF-Con rats.
Tan Y et al . GTP for NAFLD
3810 June 7, 2017|Volume 23|Issue 21|WJG|www.wjgnet.com
Therefore, it is important to control NAFLD at the initial 
stage. Here, we report for the first time that GTP can 
protect against HFD-induced NAFLD in genetically 
obese rats. HFD-fed Zucker fatty rats recapitulated 
the key metabolic features seen in humans with 
NAFLD, including central obesity, hyperlipidemia, 
and hyperinsulinemia and elevated fasting glucose 
levels. Hepatic manifestations of NAFLD in the rats 
were evidenced by the elevated ALT and AST levels, 
increased lipids droplets and TG content in the 
liver. The parameters associated with obesity and 
metabolisms shown in Table 1 indicate that HFD-fed 
ZF rat is an optimal model of NAFLD to test preventive 
and therapeutic agents against NAFLD. 
The key finding of this study is that GTP, as a 
natural agent, protected liver damage by HFD feeding 
and genetic obese, evidenced by improved hepatic 
enzymes (AST and ALT) levels and significantly 
lowered TG content in the liver of HFD-ZF rats. Results 
attained from histological analysis showed that GTP 
also markedly reduced lipid droplets in the liver of 
HFD-ZF rats.  Elevated serum ALT and AST levels are 
the primary abnormality seen in patients with NAFLD 
and other chronic liver disease in human[23]. These 
finding indicate that GTP can protect hepatocytes 
against HFD- and obesity-induced hepatic steatosis. 
Traditionally, beneficial effects of GTP on the liver 
have been attributed to their antioxidant properties[8]. 
Accumulating evidence has revealed that NAFLD is 
strongly related to inflammation. For example, IL-6, as 
a proinflammatory cytokine, has been demonstrated 
as a potential mediator leading to NAFLD. TNFα has 
been implicated in liver fibrosis and advanced stages of 
NAFLD in human[24,25]. In this study, HFD fed obese rats 
presented systemic inflammation by markedly raised 
circulating TNFα and IL-6 levels. Although no change 















































Figure 2  Reduction of hepatic steatosis and triglyceride content with green tea polyphenols treatment. A: Images were stained with H&E to visualise 
macrovesicular steatosis in liver sections at × 400 magnification. Compared to the livers in lean control rats, a larger unstained area that consisted of fat vacuoles was 
seen in ZF control rats; B: Representative ORO staining of liver samples from lean, ZF-Con and ZF-GTP rats. A larger red area that consisted of lipid droplets (B, C: 
ORO staining; × 400 magnification) and higher triglyceride contents (D) in the livers of ZF-control rats. GTP treatment significantly reversed these changes in the liver. 
Data are expressed as mean ± SME from 6-8 rats each group. bP < 0.01, eP < 0.001 vs Lean group; dP < 0.01 vs ZF-Con group. GTP: Green tea polyphenols; ZF: 
Zucker fatty.
Tan Y et al . GTP for NAFLD
3811 June 7, 2017|Volume 23|Issue 21|WJG|www.wjgnet.com
was found in anti-inflammatory cytokine IL-10, raised 
TNFα and IL-6 were attenuated by GTP treatment. 
This funding is consistent with a recent study in which 
Xiao et al[26] reported EGCG, a major active compound 
in GTP, against HFD-induced liver fibrosis associated 
with inflammation in rats through deregulation of 
TGF/SMAD, PI3 K/Akt/FoxO1, and NF-κB pathways. 
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Figure 3  Effects of green tea polyphenols on inflammatory cytokines in circulation. TNF-α (A), IL-6 (B), IL-10 (C) and IFNγ (D) levels in serum of lean, ZF-Con 
























































Figure 4  Effects of green tea polyphenols on de novo lipogenesis pathway in the liver of Zucker fatty rats. Proteins extracted from the livers of lean, Zucker 
fatty (ZF)-Con. and ZF-GTP rats were separated by SDS-PAGE and immunoblotted with anti-p-AMPK-α, anti-AMPK-α, and anti-p-ACC: Anti-ACC. β-Actin was used 
to confirm equal protein loading. Upper panels (A and C): Immunoblot bands of detected proteins; lower panels (B and D): Quantitative analysis of corresponding 
proteins. Data are expressed as mean ± SME (n = 8). aP < 0.05 vs lean, cP < 0.05 vs ZF-Con. GTP: Green tea polyphenols; ACC: Acetyl-CoA carboxylase.
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effectively prevent and reverse inflammation-mediated 
liver damage and fibrosis in rats, suggesting that GTP 
is beneficial in humans with NAFLD-induced by dietary 
factors and genetic obesity. 
In addition to anti-inflammatory and antioxidant 
action, protective effects of GTP on NAFLD may be 
related to improved hyperinsulinemia and hyper-
lipidaemia. In NAFLD, there is excess of (free fatty 
acids) FFAs/NEFAs delivered to the liver due to 
increased adipose lipolysis under insulin resistant 
status, which lead to hepatic steatosis by over 
conversion of FFAs into TG and cause hepatocytes 
injury-induced by lipotoxicity[27]. In this study, serum 
NEFAs level was significantly higher in HFD-ZF rats 
than the lean control, whereas, GTP treatment 
significantly attenuated the elevated NEFAs levels, 
which in turn, could reduce substrate influx to the 
liver for hepatic TG synthesis and also may diminish 
unoxidized fatty acids accumulation, therefore, 
prevent lipoperoxidative stress-induced hepatic 
injury[27,28]. Furthermore, reduction of hepatic lipids in 
GTP treated rats may be also attributed for improved 
hyperglycemia. Consequently, glucose influx to the 
liver was reduced and ultimately decreased de novo 
lipogenesis (DNL) in the liver.
Hepatic lipogenesis is the metabolic pathway by 
which acetyl-CoA carboxylase (ACC) converts acetyl-
CoA derived from glucose to fats, which involves sub-
processes of fatty acid synthesis and subsequent 
triglyceride synthesis utilizing carbohydrate in the 
liver[17]. In healthy individuals, DNL contributes < 5% 
to liver TG content, whereas in individuals with NAFLD, 
DNL contributes > 26% of liver TG[17]. The significant 
increase (approximately five fold) in DNL suggests 
that this pathway may play an important role in the 
development of NAFLD. Thus, controlling hepatic DNL 
highlights a potential therapeutic utility for alleviating 
NAFLD and preventing its potential consequences 
(NASH and HCC). DNL is regulated by complex enzyme 
cascades/pathways. Among these, AMPK-mediated 
phosphorylation of target substrates plays a critical role 
in the regulation of hepatic lipogenesis[21]. The activity 
of AMPK is stimulated by insulin through promoting 
its phosphorylation at Thr172[29], subsequently, AMPK 
activation leads to phosphorylation of ACC1 at Ser79 
and ACC2 at Ser221, causing a reduction in ACC 
activity that lowers malonyl-CoA from acetyl-CoA, 
which leads to decreased hepatic TG synthesis[30,31]. 
We have previously reported that GTP inhibits 
lipogenesis associated with enhanced expression 
of phosphorylated AMPKα and ACC proteins in 
hepatocytes[12]. To elucidate molecular mechanisms 
by which GTP improves hepatic steatosis in vivo, 
AMPK-ACC pathway was examined by immunoblotting 
analysis. We found that obese rats exposed to HFD 
expressed less AMPK Thr172 associated with reduced 
phosphorated ACC-Ser79 protein in the liver than 
the lean control rats. GTP intervention significantly 
enhanced protein expression of AMPK Thr172 and 
ACC Ser79 compared to saline-treated ZF rats, 
indicating that decreased hepatic TG and reversed 
liver histopathology are likely through diminishing 
hepatic lipogenesis in GTP-ZF rats. In addition to 
suppression of de novo lipogenesis, increased AMPK 
activity associated with inactivation of ACC by GTP 
may prevent hepatic injury by increasing fatty acid 
oxidation. Several lines of studies have demonstrated 
that reduction in malonyl-CoA secondary to AMPKα1-
mediated ACC inactivation enhance carnitine pal-
mitoyltransferase I (CPT I) activity, which in turn, 
increases in mitochondrial fatty acid oxidation by 
increasing CPT I flux[29,32]. Thus, by enhancing AMPK 
activation, reduced hepatic TG in GTP treated rats 
is due, at least in part, to suppression of hepatic 
lipogenesis and fatty acid oxidation in the liver through 
upregulating AMPK activation. 
SREBP-1c is a key transcription factor regulating the 
gene expression of key enzymes implicated in hepatic 
lipogenesis and triglyceride-rich lipoprotein secretion[33]. 
In this study, SREBP1c levels were lower in HFD-ZF rats 
and GTP enhanced expression SREBP-1c, which is likely 
to reduce hepatic triglyceride biosynthesis and out flux. 
This finding indicates that GTP inhibited lipogenesis 
also through inactivation of SREBP-1c. This finding 
explained the molecular mechanism of decreased 
serum cholesterol and TG levels in GTP-treated ZF rats. 
Significant reduction of serum ALT and AST 
levels and hepatic TG content in GTP-treated HFD 
ZF rats strongly supports that GTP can protect HFD-
induced liver damage. Mechanisms are likely to 
include anti-inflammation and suppression de novo 
lipogenesis through enhancing AMPK activation and 
promoting fatty-acid oxidation thereby reducing 
hepatic lipotocixity. In summary, we provide the 
first evidence that consistent administration of GTP 
protect genetically obese rodent against HFD induced 



































Figure 5  Expression of SREBP-1c in the liver of Zucker fatty rats. 
Immunoblots (A) and quantitative analysis of (B) SREBP-1c in liver tissue of 
chow fed lean rats and HFD fed Zucker fatty (ZF) rats treated with saline (5 mL/kg 
of body weight) or with GTP (200 mg/kg of body weight). β-Actin was used to 
confirm equal protein loading. Data are expressed as mean ± SME (n = 8). bP < 
0.01 vs lean, dP < 0.01 vs ZF-Con. GTP: Green tea polyphenols.
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with increased activation of AMPK pathway to control 
hepatic de novo lipogenesis and hepatic TG secretion. 
Our results encourage further study into the effects 
and safety for GTP conferring protection against NAFLD 
in human.
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